Biomarin Pharmaceuticals (BMRN)

Jan 13, 2025, 12:00 PM EST - 4 days ago

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

Jan 6, 2025, 8:30 AM EST - 11 days ago

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA

Nov 21, 2024, 3:00 PM EST - 2 months ago

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call

Nov 16, 2024, 10:45 AM EST - 2 months ago

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

Nov 6, 2024, 8:00 AM EST - 2 months ago

BioMarin to Participate in Three Upcoming Investor Conferences

Oct 29, 2024, 8:26 PM EDT - 2 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 4:03 PM EDT - 2 months ago

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

Oct 16, 2024, 8:30 AM EDT - 3 months ago

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET

Oct 8, 2024, 2:42 PM EDT - 3 months ago

3 Oversold Stocks with Big RSI Rebound Potential

ELV HUM

Sep 25, 2024, 3:50 PM EDT - 4 months ago

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

Sep 18, 2024, 8:00 AM EDT - 4 months ago

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

Sep 17, 2024, 5:15 PM EDT - 4 months ago

Ascendis Challenges BioMarin, But Market Response Seems Excessive

Sep 4, 2024, 1:00 PM EDT - 4 months ago

BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance

Sep 4, 2024, 7:30 AM EDT - 4 months ago

BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time

Aug 29, 2024, 8:00 AM EDT - 5 months ago

BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY

Aug 28, 2024, 5:32 PM EDT - 5 months ago

BioMarin to reduce global workforce by about 225 employees

Aug 21, 2024, 4:21 PM EDT - 5 months ago

BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024

Aug 21, 2024, 8:30 AM EDT - 5 months ago

BioMarin Announces New R&D and Business Development Leadership

Aug 19, 2024, 9:00 AM EDT - 5 months ago

BioMarin to Host 2024 Investor Day on September 4th in New York

Aug 6, 2024, 3:06 PM EDT - 5 months ago

Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance

Aug 5, 2024, 9:35 PM EDT - 5 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:03 PM EDT - 5 months ago

BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance

Aug 5, 2024, 4:01 PM EDT - 5 months ago

BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy

Jul 24, 2024, 4:05 PM EDT - 6 months ago

U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

Jul 23, 2024, 8:00 AM EDT - 6 months ago

BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET

Jun 17, 2024, 8:30 AM EDT - 7 months ago

BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health

Jun 7, 2024, 9:00 AM EDT - 8 months ago

BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress

May 8, 2024, 8:00 AM EDT - 9 months ago

BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV

May 4, 2024, 4:00 PM EDT - 9 months ago

New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting

Apr 24, 2024, 8:50 PM EDT - 9 months ago

BioMarin Pharmaceutical, Inc. (BMRN) Q1 2024 Earnings Call Transcript

Apr 24, 2024, 4:03 PM EDT - 9 months ago

BioMarin Reports Record Financial Results for the First Quarter 2024

Apr 10, 2024, 8:00 AM EDT - 10 months ago

BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET

Mar 12, 2024, 8:30 AM EDT - 11 months ago

New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

Mar 7, 2024, 8:30 AM EST - 11 months ago

BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

Mar 1, 2024, 9:00 AM EST - 11 months ago

BioMarin Scheduled to Participate in March Investor Conferences

Feb 26, 2024, 2:14 PM EST - 11 months ago

BioMarin Pharma gets DOJ subpoena on certain drug testing programs

Feb 22, 2024, 9:08 PM EST - 11 months ago

BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 4:03 PM EST - 11 months ago

BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024

Feb 8, 2024, 8:00 AM EST - 1 year ago

BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET

Feb 6, 2024, 8:30 AM EST - 1 year ago

BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress

Jan 3, 2024, 8:00 AM EST - 1 year ago

BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA

Dec 22, 2023, 11:06 AM EST - 1 year ago

Biotech stocks set for a rebound in 2024, analysts say

AMGN AZN BMY BPMC PFE VRTX XBI

Dec 20, 2023, 6:00 PM EST - 1 year ago

BioMarin settles with Elliott, adds 3 independent directors

Dec 20, 2023, 4:05 PM EST - 1 year ago

BioMarin Announces Governance Enhancements and Value Creation Initiatives

Nov 28, 2023, 8:30 AM EST - 1 year ago

BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany

Nov 7, 2023, 8:59 AM EST - 1 year ago

Exclusive: Activist investor Elliott targets drugmaker BioMarin -sources

Nov 1, 2023, 7:36 PM EDT - 1 year ago

Biomarin Pharmaceutical, Inc. (BMRN) Q3 2023 Earnings Call Transcript

Nov 1, 2023, 4:05 PM EDT - 1 year ago

BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year

Nov 1, 2023, 4:02 PM EDT - 1 year ago

BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer

Oct 20, 2023, 4:15 PM EDT - 1 year ago

U.S. FDA approves expanded use of BioMarin's dwarfism therapy